Tim is a Principal at Forbion, where he has been part of the investment team since February 2022, operating from the Munich office. His focus involves investing and building companies across therapeutic areas and modalities. Tim was part of the team that helped build Kynexis and holds observer roles on the board of AAVantgarde Bio, AIRNA, KyNexis, and Seamless Therapeutics.
Before his tenure at Forbion, Tim worked for L.E.K. Consulting as a Life Sciences Specialist. In 2021, he received his Ph.D. in Stem Cell Biology & Medicine from the University of Cambridge, where he investigated the epigenetic and transcriptional regulation of stem cell differentiation in health and disease by using and developing novel single-cell multi-omics sequencing technologies. Tim published research in multiple leading journals, including Nature, Nature Biotechnology, Nature Genetics, and Cell Stem Cell.
During his studies, Tim was involved in the organization of GapSummit 2018, the world’s first intergenerational biotech leadership forum that connected industry leaders with the next generation of biotech pioneers. Tim also completed his MSc in Regenerative Biology and Medicine from the TU Dresden and a BSc in Molecular Cell Biology from the University of Bielefeld.
Portfolio
Companies worked on by Tim Lohoff
